Next Generation Sequencing (NGS) is a disruptive technological development in the life science industry which has paved the path for the development of several breakthrough medical procedures, aimed to address the primary concern for the global health. NGS technologies have evolved in terms of resolution and accuracy, sequencing speed, throughout, and cost-effectiveness in the genomic analysis to accelerate biological and biomedical research. Considerable investments are being made by the key players in the market to develop the best sequencing technology with the ability to sequence long reeds, in short process time and with great accuracy.
The latest development in this field was on December 6, 2017, when BGI of China, one of the key market players, signed a memorandum to collaborate with Hummingbird Diagnostics of Germany to work on miRNA-based molecular diagnostic applications using next-generation sequencing technology, in particular in the areas of neurodegenerative disorders such as Alzheimer's and Parkinson's disease. Under this agreement, the partners will use Hummingbird's miRNA database and expertise in sample preparation as well as BGI's BGISEQ sequencer and analysis pipeline to develop targeted miRNA in vitro diagnostic assays.1
Earlier in October 2017, 10x Genomics and PerkinElmer announced that they have partnered to develop a workflow that combines PerkinElmer's automation technology with 10x Genomics' linked-reads for exome and whole-genome sequencing. The collaboration combines PerkinElmer's Chemagic nucleic acid extraction technology and Sciclone automation platform with the 10x Genomics' Chromium instrument, and enables sequencing to be done from as little as 1 nanogram of input DNA.2
Acknowledging the growing applications for NGS in the healthcare industry, BIS Healthcare has prepared a market intelligence report titled ‘Global Next Generation Sequencing (NGS) Market - Analysis and Forecast (2017-2024)'. According to the analyst, "the global next generation market was estimated at $4.14 billion in 2016 and is estimated to grow over $11.92 billion by 2024. With the substantial increase in the demand for genome mapping programs and diagnostics tests based on sequencing, the NGS market is expected to witness impressive growth and promises to be a lucrative field for investment."
The market is being dominated by Kits and Consumables in the product segment, however, the software sub-segment is expected to witness the highest CAGR in the forecast period from 2017 to 2024. In addition to this, the reversible terminator sequencing technology currently dominates the global NGS market, while among the emerging technologies Nanopore technology is estimated to witness the highest CAGR in the forecast period.